Understand the source comparison
Best Peptides for Gum Disease: Mechanism Comparison
BPC-157 VEGF upregulation, nitric oxide synthesis Angiogenesis, gingival wound closure Strong preclinical (rat/dog models), no human RCTs for periodontitis 200–500 mcg SC or topical gel, 2–3× weekly Best evidence for direct vascular repair in inflamed tissue.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, nitric oxide synthesis
- Angiogenesis, gingival wound closure
- Strong preclinical (rat/dog models), no human RCTs for periodontitis
- 200–500 mcg SC or topical gel, 2–3× weekly
- Best evidence for direct vascular repair in inflamed tissue. Mechanism directly addresses attachment loss
- TB-500 (Thymosin Beta-4 fragment)
- Actin binding, fibroblast migration
- Epithelial migration, collagen deposition
- Moderate preclinical, limited human oral wound data
- 2–10 mg SC every 3–5 days
- Strongest for post-surgical repair when mechanical debridement creates acute wound
- Thymosin Alpha-1
- T-cell modulation, cytokine regulation
- Immune balance, inflammation reduction
- Moderate human data (oral mucositis), no periodontal-specific trials
- 1.6 mg SC twice weekly
- Adjunct only. Reduces inflammatory environment but doesn't drive tissue repair directly
- Thymosin Beta-4 (full peptide)
- G-actin sequestration, anti-inflammatory cytokine release
- Fibroblast motility, ECM remodeling
- Strong preclinical, Phase 2 human oral mucositis trial
- 5–10 mg topical gel or SC injection
- Full peptide shows broader anti-inflammatory effects than TB-500 fragment but higher cost
- KPV (tripeptide)
- Alpha-MSH receptor activation, NF-κB inhibition
- Inflammatory cytokine suppression
- Emerging preclinical, no periodontal-specific studies
- 500 mcg–2 mg topical or SC
- Promising for localised inflammation control but insufficient evidence for tissue regeneration